NeuOrphan Pty Ltd is a pioneering company in the Life Sciences and Biotechnology sector. We are dedicated to developing a novel drug to treat individuals living with multiple sclerosis (MS) and other neurological disorders. Our drug, currently in the preclinical stage of development, aims to protect the central nervous system from inflammatory damage and promote repair through remyelination, addressing the unmet medical need in patients with MS progression.
Dr Steven Petratos Founder of NeuOrphan Pty Ltd
in the news
Our lead drug candidate improves neurological recovery in experimental mice with MS-like disease.
Meet NeuOrphan Pty Ltd
Mr Sam Paul Nastas CEO
Founder & Director
"Our aim is to accelerate our research findings over the last 10-years to allow people living with multiple sclerosis to have a new option to treat their progressive symptoms."
Meet NeuOrphan Pty Ltd
Dr Steven Petratos PhD
Founder & Director
Chief Scientific Officer
"We have made huge strides in understanding how multiple sclerosis progresses in people living with the disease. We now need to immediately address this unmet medical need by stopping and repairing the damage to the brain, spinal cord and optic nerve that occurs over time, so that people can have a better quality of life."
Our Services
Research and Development
Clinical Trials
Regulatory Approval
NeuOrphan's Goal
NeuOrphan's groundbreaking drug has the potential to significantly improve the quality of life of people living with multiple sclerosis.
Investors: Register your interest
Contact Us
